Home » Topics » Neurology/psychiatric, BioWorld Science

Neurology/psychiatric, BioWorld Science
RSS

Novel triple reuptake inhibitor shows antidepressant activity in animal models

May 19, 2006

FDA approves Azilect for Parkinson's disease

May 19, 2006

TC-1734 reaches endpoints in age-associated memory impairment phase II trials

May 19, 2006

BioMS Medical receives approval to begin phase II RRMS trial

May 19, 2006

Exelon recommended by FDA Advisory Committee for additional indication

May 18, 2006

FDA approves Cesamet for cancer chemotherapy-associated nausea and vomiting

May 18, 2006

Jurnista completes European mutual recognition procedure

May 18, 2006

Axonyx completes phase I clinical trial with Posiphen

May 18, 2006

TorreyPines Therapeutics' tezampanel completes phase I trials for acute migraine

May 18, 2006

Dextromethorphan/quinidine improves pseudobulbar affect in multiple sclerosis

May 18, 2006

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...